Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 46 of 46 entries
View as:

A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.

Phase: N/A Priority: Normal
NCT ID: NCT01736761 Org: User:
Start: 12/31/12 End: 03/31/15 Due: 03/31/16

The Effect of Hyperbilirubinemia on CV Disease, Neurocog Function and Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT01475240 Org: User:
Start: 01/31/12 End: 11/30/13 Due: 11/30/14

Pre-Exposure Prophylaxis Using TMC278LA

Phase: N/A Priority: Normal
NCT ID: NCT01049932 Org: User:
Start: 03/31/10 End: 05/31/10 Due: 05/31/11

The Pharmacology/Aging Clinic

Phase: N/A Priority: Normal
NCT ID: NCT01286623 Org: User:
Start: 04/01/11 End: 06/06/13 Due: 06/06/14

The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03094507 Org: User:
Start: 04/19/17 End: 03/17/18 Due: 03/17/19

PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02631473 Org: User:
Start: 11/30/15 End: - Due: -

Boceprevir and Ucalm (St John&Apos;s Wort)

Phase: N/A Priority: Normal
NCT ID: NCT01663922 Org: User:
Start: 08/31/12 End: 12/31/12 Due: 12/31/13

Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.

Phase: N/A Priority: Normal
NCT ID: NCT01275443 Org: User:
Start: 01/31/11 End: 06/30/12 Due: 06/30/13

Renal Integrase Study

Phase: N/A Priority: Normal
NCT ID: NCT02351908 Org: User:
Start: 03/31/15 End: 04/30/17 Due: 04/30/18

Evolution of Cellular and Viral Resistance in HIV-infected Patients With Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01330342 Org: User:
Start: 05/31/11 End: 05/31/14 Due: 05/31/15

SSAT067 PK of Atazanavir/Cobicistat and Darunavir/Cobicistat

Phase: N/A Priority: Normal
NCT ID: NCT02589158 Org: User:
Start: 11/30/15 End: 03/31/16 Due: 03/31/17

A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01841593 Org: User:
Start: 04/30/13 End: 09/30/13 Due: 09/30/14

Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity

Phase: N/A Priority: Normal
NCT ID: NCT02285374 Org: User:
Start: 11/30/14 End: 12/31/15 Due: 12/31/16

Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens

Phase: N/A Priority: Normal
NCT ID: NCT01049204 Org: User:
Start: 07/31/09 End: 06/30/11 Due: 06/30/12

Hydroxychloroquine for Discordant CD4 Responders on Highly Active Antiretroviral Therapy (HAART)

Phase: N/A Priority: Normal
NCT ID: NCT01232660 Org: User:
Start: 10/31/10 End: 08/31/14 Due: 08/31/15

PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation

Phase: N/A Priority: Normal
NCT ID: NCT03253757 Org: User:
Start: 09/01/17 End: 09/01/20 Due: 09/01/21

Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid

Phase: N/A Priority: Normal
NCT ID: NCT02832778 Org: User:
Start: 11/21/16 End: 02/28/18 Due: 02/28/19

Double Protease Inhibitor to Darunavir Switch Study

Phase: N/A Priority: Normal
NCT ID: NCT00531557 Org: User:
Start: 09/30/07 End: 11/30/08 Due: 11/30/09

Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01047995 Org: User:
Start: 06/30/09 End: 12/31/09 Due: 12/31/10

Depot Contraception With and Without Lopinavir/Ritonavir

Phase: N/A Priority: Normal
NCT ID: NCT01231451 Org: User:
Start: 12/31/10 End: 06/30/11 Due: 06/30/12

Targeted Clinical Strategies and Low Level Viraemia (LLV) in Boosted Protease Inhibitor Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02354209 Org: User:
Start: 03/31/15 End: 07/30/18 Due: 07/30/19